Étiquette : prescription

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome, Blathnaid McCoy et al., 2018

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome Blathnaid McCoy, Laura Wang, Maria Zak, Sameer Al-Mehmadi, Nadia Kabir, Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli & O. Carter Snead III Annals of Clinical and Translational Neurology, 2018, 5, (9), 1077–1088 doi: 10.1002/acn3.621   Abstract Introduction : Both D9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD) components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils are used to treat seizures in drug-resistant epilepsy (DRE). Recent trials provide data on dosing, side effects, and efficacy of CBD, yet there is a paucity of information on THC in epilepsy. Primary [...]

Lire la suite

Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine, Samuel T. Wilkinson et al., 2019

Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine Samuel T. Wilkinson, David H. Howard,  Susan H. Busch JAMA Published online August 2, 2019 doi:10.1001/jama.2019.10728   Major depressive disorder (MDD) affects approximately 17.3 million adults in the United States,1 with a 12-month and lifetime prevalence of 10.4% and 20.6%, respectively.2 Conducting clinical trials and developing new treatments for depression can be difficult because of spontaneous recovery rates and placebo effects.3 In addition, many patients with chronic and refractory MDD do not experience clinical improvement even after several treatment courses. There is growing interest in the use of exercise and improved nutrition to treat depression,4 [...]

Lire la suite

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial, Jose M. Trigo et al., 2018

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial Jose M. Trigo, Alexandra Soliman, Lena C. Quilty, Benedikt Fischer, JuÈrgen Rehm, Peter Selby, Allan J. Barnes11¤a, Marilyn A. Huestis, Tony P. George, David L. Streiner, Gregory Staios, Bernard Le Foll PLoS ONE, 2018, 13, (1), e0190768. https://doi.org/10.1371/journal.pone.0190768   Abstract Background The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the [...]

Lire la suite

Fluorinated Cannabidiol Derivatives : Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects, Aviva Breuer et al., 2016

Fluorinated Cannabidiol Derivatives : Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole, Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José, A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS ONE, Research Article, 2016 | DOI:10.1371/journal.pone.0158779  July 14, 2016   Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharmacological assays, including mice tests for anxiety, obsessive-compulsive disorder, depression and schizophrenia. In human trials [...]

Lire la suite

Cannabidiol as a Potential Treatment for Anxiety Disorders, Blessing E.M. et al., 2015

Cannabidiol as a Potential Treatment for Anxiety Disorders. Blessing E.M.; Steenkamp M.M.; Manzanares J.; Marmar C.R. Neurotherapeutics, 2015, 12, 4, 825-36 doi:10.1007/s13311-015-0387-1 (ISSN: 1878-7479)   Abstract : Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, [...]

Lire la suite

Cannabis thérapeutique : «Tous les voyants sont au vert», Libération, Charles Delouche, 29 mai 2019

Cannabis thérapeutique : «Tous les voyants sont au vert» Par Charles Delouche — 29 mai 2019 à 18:50 Libération Alors que l’Agence nationale du médicament doit rendre son projet d'expérimentation du cannabis thérapeutique fin juin, le Sénat a débattu du sujet ce mercredi à l’initiative d’Esther Benbassa, sénatrice EE-LV de Paris. Battre le fer tant qu’il est chaud. C’est l’idée qui animait le débat sans vote qui s’est déroulé ce mercredi au Sénat autour du cannabis thérapeutique à l'initiative d'Esther Benbassa, sénatrice Europe Ecologie-les Verts (EE-LV) de Paris. La veille, une conférence de presse était organisée aux côtés de [...]

Lire la suite

Cannabis for refractory epilepsy in children : a review focusing on CDKL5 Deficiency Disorder, Tristan Dale et al., 2019

Cannabis for refractory epilepsy in children : a review focusing on CDKL5 Deficiency Disorder Tristan Dale, Jenny Downs, Heather Olson, Ann Marie Bergin, Stephanie Smith and Helen Leonard Epilepsy Research, 2019 DOI: https://doi.org/doi:10.1016/j.eplepsyres.2019.02.001   Abstract Severe paediatric epilepsies such as CDKL5 Deficiency Disorder (CDD) are extremely debilitating, largely due to the early-onset and refractory nature of the seizures. Existing treatment options are often ineffective and associated with a host of adverse effects, causing those that are affected to seek alternative treatments. Cannabis based products have attracted significant attention over recent years, primarily driven by reports of miraculous cures and a renewed public preference for ‘natural’ therapies, [...]

Lire la suite